Revere Asset Management’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Revere Asset Management’s Portfolio LABU Stock Details LABU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$666K	Buy	+2,279	New	+$436K	0.26%	21

Other funds holding LABU

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

MIG

McGuire Investment Group Wakefield, Rhode Island $1.14B AUM 79.59% 1-Year Est. Return

CBU

CIBC Bancorp USA Chicago, Illinois $82.3B AUM

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

EFG

Ethos Financial Group King Of Prussia, Pennsylvania $1.5B AUM 22.75% 1-Year Est. Return

Revere Asset Management's LABU Position: Q2 2026 in Review

Revere Asset Management opened a new position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q2 2026: 2,279 shares worth $666K. The stake represents 0.26% of the portfolio and ranks #21 among its holdings.

37 funds tracked by Wall St. Rank hold LABU as of Q2 2026.

Revere Asset Management held 2,279 shares of Direxion Daily S&P Biotech Bull 3X ETF worth $666K as of Q2 2026.
Direxion Daily S&P Biotech Bull 3X ETF was a new Revere Asset Management position in Q2 2026.
Direxion Daily S&P Biotech Bull 3X ETF made up 0.26% of Revere Asset Management's portfolio in Q2 2026, its #21 holding.
37 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q2 2026.

Based on Revere Asset Management's 13F filing for Q2 2026, filed 14 Sep 2026.